Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v3.19.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Cash Flows from Operating Activities:    
Net loss $ (16,255) $ (38,218)
Net loss on discontinued operations 0 (2,076)
Loss from continuing operations (16,255) (36,142)
Reconciliation of net loss to net cash used in operating activities:    
Depreciation expense 481 196
Amortization of debt discount 622 661
Amortization of product revenue license fee 234 133
Amortization of operating lease right-of-use assets 381  
Stock-based compensation expense 3,309 4,795
Common shares issuable for Opus interest expense 281  
Common shares issuable for 2017 Subordinated Note Financing interest expense 484 489
Change in fair value of investments 0 118
Change in fair value of derivative liability   (23)
Change in fair value of partner company convertible note 0 (250)
Gain on deconsolidation of Caelum (18,384)  
Research and development-licenses acquired, expense 450 97
Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:    
Accounts receivable (2,524) (556)
Inventory 49 (51)
Other receivables - related party (34) (326)
Prepaid expenses and other current assets 2,483 (1,466)
Other assets (949) (343)
Current assets held for sale   (3,383)
Noncurrent assets held for sale   427
Current liabilities held for sale   4,040
Accounts payable and accrued expenses 3,664 6,195
Accounts payable and accrued expenses - related party (133) (98)
Interest payable (21) 17
Interest payable - related party   (12)
Lease liabilities (351)  
Other long-term liabilities 888 19
Net cash used in continuing operating activities (25,325) (25,463)
Net cash used in discontinued operating activities   (2,381)
Net cash used in operating activities (25,325) (27,844)
Cash Flows from Investing Activities:    
Purchase of research and development licenses   (75)
Purchase of property and equipment (300) (765)
Purchase of short-term investment (certificates of deposit)   (25,000)
Redemption of short-term investment (certificates of deposit) 12,560 24,000
Deconsolidation of Caelum (1,201)  
Net cash provided by (used in) continuing investing activities 11,059 (1,840)
Net cash provided by discontinued investing activities 13,089  
Net cash provided by (used in) investing activities 24,148 (1,840)
Cash Flows from Financing Activities:    
Payment of Preferred A dividends (586) (586)
Inter-company costs related to the issuance of Series A preferred stock 1,298
Proceeds from at-the-market offering 6,251 229
Payment of cost related to at-the-market offering (109) (6)
Proceeds from partner company's sale of stock 34,999 23,011
Payment of costs related to partner company's sale of stock (3,500) (2,167)
Proceeds from partner company's at-the-market offering 366  
Payment of costs related to partner company's at-the-market offering (11)  
Proceeds from exercise of partner companies' warrants   96
Payment of debt issuance costs associated with 2017 Subordinated Note Financing   (255)
Proceeds from 2018 Venture Notes   21,707
Payment of debt issue costs associated with 2018 Venture Notes (67) (1,814)
Proceeds from partner company's Horizon Notes 15,000  
Payment of debt issuance costs associated with partner company's Horizon Notes (230)  
Payment of partner company's Convertible Notes   (1,858)
Net cash provided by financing activities 52,113 39,655
Net increase in cash and cash equivalents and restricted cash 50,936 9,971
Cash and cash equivalents and restricted cash at beginning of period 81,582 110,958
Cash and cash equivalents and restricted cash at end of period 132,518 120,929
Supplemental disclosure of cash flow information:    
Cash paid for interest 1,100 394
Cash paid for interest - related party   853
Supplemental disclosure of non-cash financing and investing activities:    
Settlement of restricted stock units into common stock 2 1
Receivable from ATM issuances   89
Unpaid debt offering costs 1,202  
Common shares issuable for license acquired 164  
Common shares issued for 2017 Subordinated Note Financing interest expense 495 500
Issuance of partner company warrants in conjunction with Horizon Notes 888  
Unpaid fixed assets 191 2,321
Inter-company costs related to the issuance of Series A preferred stock $ 1,298